Related Experiment Video
Updated: Mar 12, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Pharmacogenomics competencies in pharmacy practice: A blueprint for change
Journal of the American Pharmacists Association : Japha
|November 7, 2016
Summary
Pharmacogenomic data informs medication therapy, but pharmacists lack confidence in its application. Updated competencies are needed to integrate genomic data into patient care and advance pharmacist roles.
Area of Science:
- Pharmacogenomics
- Genomic Data Integration
- Clinical Pharmacy Practice
Background:
- Genomic data is increasingly used to guide medication therapy, influencing drug prescribing information.
- Despite available pharmacogenomic studies, many pharmacists lack confidence in applying this data to patient care.
- Initial pharmacogenomics competency statements for pharmacists were established in 2002.
Purpose of the Study:
- To update the pharmacogenomics competency statement for pharmacists.
- To reflect advancements in genomic science and the necessity for pharmacist application of genomic data.
- To address the need for standardized pharmacist education and training in pharmacogenomics.
Main Methods:
- A consensus-based method was employed for updating the competency statement.
- Input was gathered from multiple key professional pharmacy organizations.
- The process aimed to incorporate the growth of genomic science and its practical application.
Main Results:
- The update reflects the evolving landscape of genomic science and its clinical relevance.
- Identified a need for enhanced pharmacist competency in utilizing genomic data.
- Highlighted the importance of professional consensus in defining standards.
Conclusions:
- A standardized, competency-based approach to pharmacogenomics education is essential for pharmacists.
- Pharmacists require updated training to effectively lead in the clinical utilization of genomic data.
- Equipping pharmacists is crucial for their role in healthcare teams implementing genomic strategies.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
11.2K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.7K
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
109
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
109
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
83
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
01:29Pharmacogenomics: Identification of New Drug Targets
61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
01:27Pharmacogenetics of Drug Metabolism: Overview
85
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
85
01:27Principles of Pharmacogenetics: Types of Genetic Variants
70
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
70
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
87
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
87